Sandoz Gains US Rights to Anacor’s Topical Drug Kerydin
Sandoz, the generics business of Novartis, has formed an agreement with Anacor Pharmaceuticals, Inc., a pharmaceutical company focused on discovering, developing, and commercializing small-molecule therapeutics derived from the company’s boron chemistry platform, to obtain exclusive rights to commercialize Anacor's drug Kerydin (tavaborole) topical solution, 5% in the US, through its branded dermatology business, PharmaDerm.
Earlier this month, Anacor received approval by the US Food and Drug Adminstration for Kerydin, an oxaborole antifungal approved for the topical treatment of onychomycosis of the toenails due to Trichophyton rubrum or Trichophyton mentagrophytes, a fungal infection of the nail and nail bed. The agreement was effective July 18, 2014.
Source: Sandoz